PHAR vs. HCM, EWTX, KYMR, AMRX, JANX, ARWR, NAMS, PTGX, CGON, and VERA
Should you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include HUTCHMED (HCM), Edgewise Therapeutics (EWTX), Kymera Therapeutics (KYMR), Amneal Pharmaceuticals (AMRX), Janux Therapeutics (JANX), Arrowhead Pharmaceuticals (ARWR), NewAmsterdam Pharma (NAMS), Protagonist Therapeutics (PTGX), CG Oncology (CGON), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry.
Pharming Group vs.
Pharming Group (NASDAQ:PHAR) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment.
HUTCHMED received 295 more outperform votes than Pharming Group when rated by MarketBeat users. Likewise, 66.32% of users gave HUTCHMED an outperform vote while only 64.52% of users gave Pharming Group an outperform vote.
HUTCHMED has higher revenue and earnings than Pharming Group.
Pharming Group has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500.
Pharming Group presently has a consensus price target of $27.00, indicating a potential upside of 169.73%. HUTCHMED has a consensus price target of $19.00, indicating a potential upside of 33.80%. Given Pharming Group's stronger consensus rating and higher probable upside, analysts clearly believe Pharming Group is more favorable than HUTCHMED.
0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by insiders. Comparatively, 3.6% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
HUTCHMED has a net margin of 0.00% compared to Pharming Group's net margin of -6.09%. HUTCHMED's return on equity of 0.00% beat Pharming Group's return on equity.
In the previous week, HUTCHMED had 1 more articles in the media than Pharming Group. MarketBeat recorded 5 mentions for HUTCHMED and 4 mentions for Pharming Group. HUTCHMED's average media sentiment score of 0.80 beat Pharming Group's score of 0.70 indicating that HUTCHMED is being referred to more favorably in the news media.
Summary
HUTCHMED beats Pharming Group on 13 of the 16 factors compared between the two stocks.
Get Pharming Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pharming Group Competitors List
Related Companies and Tools
This page (NASDAQ:PHAR) was last updated on 1/21/2025 by MarketBeat.com Staff
